Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34461733 | 0.86 | ADORA2A (0.38) | ALDH1A1ADORA2ALMNAMAPK1 | |
| SCHEMBL34461760 | 0.84 | GRIA1 (0.32) | ALDH1A1KMT2AF2RL3MAOAMAOB | |
| SCHEMBL34461744 | 0.83 | ALDH1A1 (0.37) | ALDH1A1ADORA2ALMNA | |
| SCHEMBL34461734 | 0.82 | ALDH1A1 (0.36) | ALDH1A1KMT2AADORA2ALMNA | |
| SCHEMBL34461722 | 0.73 | TRPA1 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL34461757 | 0.71 | ADORA2A (0.62) | ALDH1A1ADORA2AMAOAMAOBMCL1 | |
| SCHEMBL34461749 | 0.70 | ADORA2A (0.41) | ALDH1A1KMT2AADORA2AEGFRADORA3 | |
| SCHEMBL34461772 | 0.68 | CYP1A2 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL34461724 | 0.66 | GRIK1 (0.39) | ALDH1A1KMT2AMAPK1 | |
| SCHEMBL34461790 | 0.66 | HCAR1 (0.33) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | ALDH1A1 1354/4885KMT2A 3313/4885ADORA2A 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.